Učitavanje...
Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia
Cis-diamminedichloroplatinum (II) (cisplatin) is the most widely used chemotherapeutic drug for various cancers, but its effectiveness is limited by tumor cell resistance and the severe side effects it causes. Since high level of cisplatin is cytotoxic to both cancer and normal cells, the goal of th...
Spremljeno u:
| Izdano u: | Int J Cancer Res Mol Mech |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758698/ https://ncbi.nlm.nih.gov/pubmed/26900603 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|